# EDGAR Filing Document

**Accession Number:** 0000749647
**File Stem:** 0001437749-25-020661
**Filing Date:** 2025-6
**Character Count:** 6482
**Document Hash:** 65f02da47610038253f0c34b6cb6f6b0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-25-020661.hdr.sgml**: 20250617

**ACCESSION NUMBER**: 0001437749-25-020661

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250613

**FILED AS OF DATE**: 20250617

**DATE AS OF CHANGE**: 20250617

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Bragg Kimberly
- **CENTRAL INDEX KEY:** 0001814159

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-15911
- **FILM NUMBER:** 251053664

**MAIL ADDRESS:**
- **STREET 1:** C/O TIMBER PHARMACEUTICALS, INC.
- **STREET 2:** 900 E. HAMILTON AVENUE, SUITE 100
- **CITY:** CAMPBELL
- **STATE:** CA
- **ZIP:** 95008
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Imunon, Inc.
- **CENTRAL INDEX KEY:** 0000749647
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 521256615
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 997 LENOX DRIVE
- **STREET 2:** SUITE 100
- **CITY:** LAWRENCEVILLE
- **STATE:** NJ
- **ZIP:** 08648
- **BUSINESS PHONE:** (609) 896-9100

**MAIL ADDRESS:**
- **STREET 1:** 997 LENOX DRIVE
- **STREET 2:** SUITE 100
- **CITY:** LAWRENCEVILLE
- **STATE:** NJ
- **ZIP:** 08648

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Celsion CORP
- **DATE OF NAME CHANGE:** 20071121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CELSION CORP
- **DATE OF NAME CHANGE:** 19980515

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CHEUNG LABORATORIES INC
- **DATE OF NAME CHANGE:** 19920703

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Bragg Kimberly<br><sub>(Last) (First) (Middle)</sub><br>C/O IMUNON, INC.<br>997 LENOX DRIVE, SUITE 100<br><sub>(Street)</sub><br>LAWRENCEVILLE, NJ 08648<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Imunon, Inc. [ IMNN ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2025-06-13 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_CFO_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 2000 | D |  |
| Common Stock | 18400 | I | By 401(k) Plan |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | 2023-10-17<sup>(1)</sup> | 2032-10-17 | Common Stock | 10000 | $1.4000 | D |  |
| Stock Option (Right to Buy) | 2023-03-17<sup>(2)</sup> | 2033-03-17 | Common Stock | 7500 | $1.3200 | D |  |
| Stock Option (Right to Buy) | 2024-03-15<sup>(3)</sup> | 2034-03-15 | Common Stock | 10000 | $0.8600 | D |  |
| Stock Option (Right to Buy) | 2024-06-12<sup>(4)</sup> | 2034-06-12 | Common Stock | 10000 | $1.2200 | D |  |
| Stock Option (Right to Buy) | 2024-09-06<sup>(5)</sup> | 2034-09-06 | Common Stock | 13227 | $1.0400 | D |  |
| Stock Option (Right to Buy) | 2025-03-14<sup>(6)</sup> | 2035-03-14 | Common Stock | 10000 | $0.8700 | D |  |

---

### Footnotes:

(1) The options vest as follows: one-third on October 17, 2023, the first anniversary of the date of grant; one-third on the second year anniversary of the date of grant; and one-third on the third year anniversary of the date of grant.

(2) The options vest as follows: one-third on the date of grant, March 17, 2023; one-third on the first anniversary of the date of grant; and one-third on the second year anniversary of the date of grant.

(3) The options vest as follows: one-half on the date of grant, March 15,2024; one-fourth on the first anniversary of the date of grant; and one-fourth on the second year anniversary of the date of grant.

(4) The options vest as follows: one-half on the date of grant, June 12,2024; one-fourth on the first anniversary of the date of grant; and one-fourth on the second year anniversary of the date of grant.

(5) The options vest as follows: one-half on the date of grant, September 6,2024; one-fourth on the first anniversary of the date of grant; and one-fourth on the second year anniversary of the date of grant.

(6) The options vest as follows: one-half on the date of grant, March 14, 2025; one-fourth on the first anniversary of the date of grant; and one-fourth on the second year anniversary of the date of grant.

**Signature:** /s/ Kimberly Graper  
**Date:** 2025-06-17

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**